As part of the organisational overhaul unveiled in April, Novartis said that the cost cuts would be mainly from removing overlapping structures
→ Google Tradutor
Novartis'' (NVS) restructuring activities could lead to reduction of up to 8K jobs, including up to 1.4K in Switzerland, Swiss newspaper TagesAnzeiger reported.The job cuts are part of…
→ Google Tradutor
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS), Medallion Financial Corp. (NASDAQ: MFIN), RBB Bancorp (NASDAQ: RBB), and Agrify Corporation (NASDAQ: AGFY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
→ Google Tradutor
A committee of the European Medicines Agency (EMA) recommended the approval of Novartis'' (NVS) Scemblix to treat adult patients with Philadelphia chromosome‑positive chronic…
→ Google Tradutor
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at le…
→ Google Tradutor
Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization for Scemblix ® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). If approved, Scemblix will be the first CML treatment in Europe that works by specifically targeting the ABL myristoyl pocket (also known as a STAMP inhibitor in scientific literature), representing an important therapeutic advancement for patients who experience intolerance and/or resistance to currently available TKI therapies 1 .
→ Google Tradutor
The FDA granted accelerated approval to Novartis AG''s (NYSE: NVS ) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer. Individuals … Full story available on Benzinga.com
→ Google Tradutor
CVS Caremark will return the Eliquis blood thinner to its formulary, reversing a decision that sparked protests from physicians and patients.
→ Google Tradutor
FRANKFURT — A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumors that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumor agnostic. The Food and Drug Administration early on Thursday granted accelerated approval […]
→ Google Tradutor
Precision BioSciences is developing gene editing tools with several potential advantages over CRISPR.
→ Google Tradutor
The latest research on "Cold, Cough and Sore Throat Remedies Report 2021" offered by HTF MI provides a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the
→ Google Tradutor
Novartis AG (NVS)’s stock has witnessed a price hike of 0.46% from the previous close with its current price standing at $81.86. Its current price is -13.98% under its 52-week high of $95.17 and 3.51% more than its 52-week low of $79.09. Based on the past 30-day period, the stock price is -11.35% below the … Is Novartis AG (NYSE:NVS) stock a better investment at this time? Read More »
→ Google Tradutor
Source: GaudiLab / Shutterstock Exela Technologies (NASDAQ: XELA ) stock is taking off on Wednesday after gaining a new $136 million customer contract . According to a press release from the company, its Exchange for Bills and Payments (XBP) has continued to sign new logos contracts. This newest batch has it set to earn $136 million over the course of the next three years. So what exactly does all that mean? Exela Technologies is a business process automation company that helps companies make their workflow more efficient. It does so through the use of its payment processing, workflow, and digital mailroom services. Exela Technologies also mentions that this new contract brings its year-to-date total contract value to $175 million. That’s a strong start for its XBP business, which produced revenue of $874.2 million during fiscal 2021. 7 Bargain Income Stocks to Buy and Hold Forever Lakshmi Narayanan Chandramohan, president of Bills and Payments at Exela Technologies, said this in the news release. “This win highlights our scalable, referenceable XBP platforms effectiveness for rapid deployment for our customers.
→ Google Tradutor
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 - Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding t…
→ Google Tradutor
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for Gilenya. Novartis plans to file a petition seeking further review of this decision. In August 2020, the U.S. District
→ Google Tradutor
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for Gilenya. Novartis plans to file a…
→ Google Tradutor
An investigation for investors in Novartis AG (NYSE:NVS) shares over potential securities laws violations by Novartis AG was announced. San Diego, CA -- ( SBWIRE ) -- 06/17/2022 -- Novartis AG is under investigation concerning potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Novartis AG (NYSE: NVS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by Novartis AG regarding its business, its prospects and its operations were materially false and misleading at the time they were made. Switzerland based Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. On May 5, 2022, Novartis AG "announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey." The production halt was to "address potential quality issues identified in its manufacturing process." Shares of Novartis AG (NYSE: NVS) declined from $88.50 per share on May 4, 2022, to $83.37 per share on May 9, 2022.
→ Google Tradutor
AstraZeneca is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma , The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist''s partners, which include Novartis , OncXerna and Ultragenyx . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
→ Google Tradutor
-- Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study -- Adalimumab''s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients -- Submission builds on Sandoz'' well established biosimilar…
→ Google Tradutor
NVS, UL, MO, MMM, BTI, FLIC, ENB, BNS, TD, MMP, EPD, and MURGY are 12 of the best high-yield, low volatility blue-chip bargains on Wall Street today. Read more.
→ Google Tradutor
Deciphera Pharmaceuticals (DCPH) appointed Kelley Dealhoy as senior vice president and chief business officer.Waltham, Mass.-based Deciphera said in a June 16 release that Dealhoy…
→ Google Tradutor
Pliant Therapeutics (PLRX) said it advanced a fibrosis-directed integrin target into development as part of a 2019 collaboration with Novartis (NVS).The South San…
→ Google Tradutor
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the advancement of a fibrosis-directed integrin target into development as part of the Company’s 2019 research and development collaboration with Novartis. This initiation of work follows Pliant’s successful achievement of target validation under the agreement.
→ Google Tradutor
-- COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services -- Report from the Broadband Commission for Sustainable Development Working Group on Virtual Health and Care -- co-chaired by the World…
→ Google Tradutor
The migraine market is expected to surge due to the increasing prevalence of the disease along with increasing awareness during the forecast period. Furthermore, the launch of various multiple-stage pipeline products will significantly revolutionize the migraine market dynamics. LAS VEGAS , June 15, 2022 /PRNewswire/ -- DelveInsight''s Migraine Market Insights report includes a comprehensive understanding of current treatment practices, Migraine emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM ( the United States , the EU5 (the United Kingdom , Italy , Spain , France , and Germany ), and Japan . Key Takeaways from the Migraine Market Report As per DelveInsight analysis, the migraine market size in the 7MM was approximately USD 6.9 billion in 2021. As per the estimates, the total Migraine prevalent cases in the 7MM was approximately 118 million in 2021. Leading Migraine companies such as Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr.
→ Google Tradutor
VFC, NVS, CSCO, ALIZY, MMM, EPD, & MO represent 7 of the world''s safest dividend blue-chips in 7 sectors that create a diverse stock portfolio. See more here.
→ Google Tradutor
GSK plc with ticker code (GSK) have now 3 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 52.5 and 45.94 calculating the average target price we see 49.81. Given that the stocks previous close was at 42.5 this would indicate that there is a potential upside of 17.2%. The day 50 moving average is 44.5 and the 200 day MA is 42.69. The market capitalisation for the company is $103,756m. Visit the company website at: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $121,602m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
→ Google Tradutor
The global pharmaceutical drugs market size is expected to grow from $ 1,075.97 billion in 2021 to $1,136.23 billion in 2022 at a compound annual growth rate (CAGR) of 5.6%. The growth in the market is mainly due to the
→ Google Tradutor
DUBLIN--(BUSINESS WIRE)--The "Analgesics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com''s offering. The global analgesics market reached a value of US$ 49.02 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 64.59 Billion by 2027, exhibiting a CAGR of 4.5% during 2022-2027. Companies Mentioned Bayer AG Novartis International AG GlaxoSmithKline PLC Pfizer Inc. Johnson & Joh
→ Google Tradutor
DUBLIN , June 14, 2022 /PRNewswire/ -- The "Axial Spondyloarthritis Market - A Global and Country Analysis: Focus on Commercialized Therapies, Potential Pipeline Products, Indication, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com''s offering. The global axial spondyloarthritis market was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032. The growth in the global axial spondyloarthritis market is expected to be driven by the introduction of novel products, the increasing awareness about the disease, and the rising research and development investments, among others. Market Lifecycle Stage The global axial spondyloarthritis market is well established. Biopharmaceutical companies are trying to match themselves with new technologies in the market to improve the overall system from drug discovery to drug commercialization. The companies operating in the global axial spondyloarthritis market are now focusing more on biologics and personalized therapy to enhance therapeutics and improve patient outcomes.
→ Google Tradutor
Major players in the pharmacovigilance market are Accenture, Cognizant, Labcorp Drug Development, IQVIA, IQVIA, Parexel International Corporation, BioClinica Inc. , Clinquest Inc. , ITClinical, TAKE Solutions Limited, United BioSource LLC, Wipro Limited, Bristol-Myers Squibb Company, Linical Americas, iMEDGlobal, Boehringer Ingelheim International GmbH, Novartis AG, Ecron Acunova Limited, and Sanofi. Major players in the pharmacovigilance market are Accenture, Cognizant, Labcorp Drug Development, IQVIA, IQVIA, Parexel International Corporation, BioClinica Inc. , Clinquest Inc. , ITClinical, TAKE Solutions Limited, United BioSource LLC, Wipro Limited, Bristol-Myers Squibb Company, Linical Americas, iMEDGlobal, Boehringer Ingelheim International GmbH, Novartis AG, Ecron Acunova Limited, and Sanofi.
→ Google Tradutor
LOW, VFC, ASML, AMAT, MA, CL, NVS, CSCO, V, and NKE are 10 of the safest dividend stocks to own in a recession. Read more about these stocks here.
→ Google Tradutor
Major players in the pain management devices and therapies market are Abbott Laboratories, AstraZeneca, Pfizer, Boston Scientific Corporation, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd, Medtronic PLC, Novartis AG, Baxter International Inc, and Johnson & Johnson. Major players in the pain management devices and therapies market are Abbott Laboratories, AstraZeneca, Pfizer, Boston Scientific Corporation, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd, Medtronic PLC, Novartis AG, Baxter International Inc, and Johnson & Johnson.
→ Google Tradutor
Companies Reporting Before The Bell • First American Financial (NYSE: FAF ) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million. • Associated Capital Group (NYSE: AC ) is expected to report earnings for its first quarter. • TransUnion (NYSE: TRU ) is estimated to report quarterly earnings at $0.92 per share on revenue of $910.77 million. • Warner Bros.Discovery (NASDAQ: WBD ) is likely to report earnings for its first quarter. • Travelzoo (NASDAQ: TZOO ) is estimated to report quarterly earnings at $0.06 per share on revenue of $16.67 million. • NexPoint Residential (NYSE: NXRT ) is likely to report quarterly loss at $0.26 per share on revenue of $60.13 million. • First Commonwealth (NYSE: FCF ) is projected to report quarterly earnings at $0.30 per share on revenue of $94.06 million. • First Merchants (NASDAQ: FRME ) is expected to report quarterly earnings at $0.87 per share on revenue of $133.52 million. • First Foundation (NASDAQ: FFWM ) is projected to report quarterly earnings at $0.
→ Google Tradutor
This report studies the Autoinjectors Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Autoinjectors market segmented by company, region, type and applications []
→ Google Tradutor
This report studies the Memantine Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Memantine market segmented by company, region, type and applications []
→ Google Tradutor
This report studies the Capecitabine Fumarate Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Capecitabine Fumarate market segmented by company, region, type []
→ Google Tradutor
This report studies the Liposomal Verteporfin Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Liposomal Verteporfin market segmented by company, region, type []
→ Google Tradutor
This report studies the Imatinib Drugs Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Imatinib Drugs market segmented by company, region, type []
→ Google Tradutor
This report studies the Candidiasis Therapeutics Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Candidiasis Therapeutics market segmented by company, region, type []
→ Google Tradutor
This report studies the Vision Care Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Vision Care market segmented by company, region, type []
→ Google Tradutor
This report studies the Weight Loss Drugs Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Weight Loss Drugs market segmented by company, []
→ Google Tradutor
This report studies the Valsartan Drug Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Valsartan Drug market segmented by company, region, type []
→ Google Tradutor
This report studies the Herpes Simplex Virus Treatment Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Herpes Simplex Virus Treatment market segmented []
→ Google Tradutor
This report studies the Neurosyphilis Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Neurosyphilis market segmented by company, region, type and applications []
→ Google Tradutor
This report studies the Biopharmaceutical Oral Drug Delivery Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Biopharmaceutical Oral Drug Delivery market segmented []
→ Google Tradutor
This report studies the Fibrosarcoma Treatment Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Fibrosarcoma Treatment market segmented by company, region, type []
→ Google Tradutor
This report studies the Intranasal Drug Delivery Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Intranasal Drug Delivery market segmented by company, []
→ Google Tradutor
This report studies the Drugs for Oncology Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Drugs for Oncology market segmented by company, []
→ Google Tradutor
- ← anterior
- 1
- 2
- 3
- …
- 20
- 21
- próximo →